Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment.
| Title: | Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. |
|---|---|
| Authors: | Cooper N; Department of Haematology, Hammersmith Hospital, Imperial College London, London, UK.; Kruse A; Platelet Disorder Support Association, Cleveland, Ohio, USA.; Kruse C; Platelet Disorder Support Association, Cleveland, Ohio, USA.; Watson S; Patient Representative for the UK ITP Forum, Bolnhurst, UK.; Morgan M; ITP Support Association, Bolnhurst, UK.; Provan D; Academic Haematology Unit, Blizard Institute, Barts and The School of Medicine and Dentistry, London, UK.; Ghanima W; Department of Medicine, Østfold Hospital Trust, Kalnes, Norway.; Department of Hematology, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Arnold DM; Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.; Tomiyama Y; Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.; Santoro C; Hematology, University Hospital Policlinico Umberto I, Rome, Italy.; Michel M; Department of Internal Medicine, National Referral Center for Adult Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France.; Laborde S; O'Cyto, Saint-Loubes, France.; Lovrencic B; Italian Association of Immune Thrombocytopenic Purpura, Caprino Veronese, Italy.; Hou M; Department of Hematology, Shandong University, Jinan, China.; Bailey T; Bespoke Team, Adelphi Real World, Macclesfield, UK.; Taylor-Stokes G; Bespoke Team, Adelphi Real World, Macclesfield, UK.; Haenig J; Novartis Pharma AG, Basel, Switzerland.; Bussel JB; Division of Hematology/Oncology, Weill Cornell Medicine, New York, New York, USA. |
| Source: | American journal of hematology [Am J Hematol] 2021 Feb 01; Vol. 96 (2), pp. 188-198. Date of Electronic Publication: 2020 Dec 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Imprint Name(s): | Publication: New York Ny : Wiley-Blackwell; Original Publication: New York, Liss. |
| MeSH Terms: | Quality of Life* ; Surveys and Questionnaires*; Purpura, Thrombocytopenic, Idiopathic/*diagnosis ; Purpura, Thrombocytopenic, Idiopathic/*therapy; Adult ; Aged ; Chronic Disease ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged |
| Abstract: | Immune thrombocytopenia (ITP) is now well-known to reduce patients' health-related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I-WISh (ITP World Impact Survey) was an exploratory, cross-sectional survey designed to establish the multifaceted impact of ITP, and its treatments, on patients' lives. It focused on perceptions of 1507 patients and 472 physicians from 13 countries regarding diagnostic pathway, frequency and severity of signs and symptoms, and treatment use. Twenty-two percent of patients experienced delayed diagnosis (caused by several factors), 73% of whom felt anxious as a result. Patients rated fatigue among the most frequent, severe symptom associated with ITP at diagnosis (58% most frequent; 73% most severe), although physicians assigned it lower priority (30%). Fatigue was one of the few symptoms persisting at survey completion (50% and 65%, respectively) and was the top symptom patients wanted resolved (46%). Participating physicians were experienced at treating ITP, thereby recognizing the need to limit corticosteroid use to newly-diagnosed or first-relapse patients and espoused increased use of thrombopoietin receptor agonists and anti-CD20 after relapse in patients with persistent/chronic disease. Patient and physicians were largely aligned on diagnosis, symptoms, and treatment use. I-WISh demonstrated that patients and physicians largely align on overall ITP symptom burden, with certain differences, for example, fatigue. Understanding the emotional and clinical toll of ITP on the patient will facilitate shared decision-management, setting and establishment of treatment goals and disease stage-appropriate treatment selection.; (© 2020 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.) |
| Comments: | Comment in: Am J Hematol. 2021 Feb 1;96(2):172-173. doi: 10.1002/ajh.26053.. (PMID: 33219702); Erratum in: Am J Hematol. 2021 Oct 1;96(10):1343. doi: 10.1002/ajh.26139.. (PMID: 34494302) |
| References: | Lancet. 2011 Jan 29;377(9763):393-402. (PMID: 20739054); Lancet. 2009 Feb 21;373(9664):641-8. (PMID: 19231632); J Thromb Haemost. 2015 Mar;13(3):457-64. (PMID: 25495497); J Thromb Haemost. 2010 Jun;8(6):1372-82. (PMID: 20230419); Eur J Haematol. 2009 Sep;83(3):175-82. (PMID: 19374704); Blood. 2008 Aug 15;112(4):999-1004. (PMID: 18463354); Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520. (PMID: 23714309); Blood. 2013 Jan 17;121(3):537-45. (PMID: 23169778); Am J Hematol. 2016 Oct;91(10):995-1001. (PMID: 27351715); Am J Hematol. 2015 Mar;90(3):E40-3. (PMID: 25400215); N Engl J Med. 2007 Nov 29;357(22):2237-47. (PMID: 18046028); Blood Adv. 2019 Nov 26;3(22):3780-3817. (PMID: 31770441); Eur J Haematol. 2017 Apr;98(4):371-377. (PMID: 27981682); Br J Haematol. 2020 Oct;191(1):98-106. (PMID: 32501532); Br J Haematol. 2014 Jun;165(6):865-9. (PMID: 24725224); Blood Adv. 2019 Dec 10;3(23):3829-3866. (PMID: 31794604); Intern Med. 2016;55(17):2379-85. (PMID: 27580537); Br J Haematol. 2004 Apr;125(2):232-9. (PMID: 15059147); Br J Haematol. 2016 Jan;172(2):262-73. (PMID: 26537623); Am J Hematol. 2021 Feb 1;96(2):199-207. (PMID: 33107998); Blood. 2017 Dec 7;130(23):2527-2536. (PMID: 29042367); Br J Haematol. 2015 Jul;170(2):141-9. (PMID: 25823426); Am J Hematol. 2021 Feb 1;96(2):188-198. (PMID: 33170956); Ann Hematol. 2002 Aug;81(8):436-40. (PMID: 12224000); Blood. 2010 Jan 14;115(2):168-86. (PMID: 19846889); Br J Haematol. 2014 Oct;167(2):243-51. (PMID: 25041261); Am J Hematol. 2018 Jul;93(7):921-930. (PMID: 29696684); Blood. 2009 Mar 12;113(11):2386-93. (PMID: 19005182); N Engl J Med. 2010 Nov 11;363(20):1889-99. (PMID: 21067381); Br J Haematol. 2017 Apr;177(1):39-54. (PMID: 28295192); Transfusion. 2013 Nov;53(11):2807-12. (PMID: 23451917); Haematologica. 2019 Jun;104(6):1124-1135. (PMID: 31126963); J Thromb Haemost. 2012 Oct;10(10):1988-98. (PMID: 22863415); Blood Adv. 2017 Nov 28;1(25):2414-2420. (PMID: 29296891); Semin Hematol. 2013 Jan;50 Suppl 1:S83-8. (PMID: 23664524); Blood. 2012 Jun 21;119(25):5989-95. (PMID: 22566601); Lancet. 2008 Feb 2;371(9610):395-403. (PMID: 18242413); Blood. 2012 Aug 2;120(5):960-9. (PMID: 22740443); Br J Haematol. 2013 May;161(3):411-23. (PMID: 23432528); Lancet. 2015 Apr 25;385(9978):1653-61. (PMID: 25662413) |
| Entry Date(s): | Date Created: 20201110 Date Completed: 20210302 Latest Revision: 20210908 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7898610 |
| DOI: | 10.1002/ajh.26045 |
| PMID: | 33170956 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't